Plasmology4

Plasmology4 is a privately held technology company based in Scottsdale, Arizona, United States, operating in the emerging field of plasma medicine. The company describes itself as pioneering the use of non-thermal plasma — ionized gas generated at atmospheric pressure and temperatures below 100°C — for human healthcare applications. Its proprietary platform, branded Plaz4, is positioned as a highly advanced and specialized form of non-thermal plasma with characteristics that distinguish it from ordinary cold plasmas. Plasmology4's first commercial product is the Plaz4 1000 system, which the company says has the potential to address two major global healthcare problems: antibiotic-resistant bacteria and non-healing chronic wounds. According to the company, in vitro studies and in vivo animal studies have demonstrated that Plaz4 can simultaneously kill pathogens, including antibiotic-resistant strains, and promote wound healing in a manner that is drug-free, painless, fast, and cost-effective. The company presents Plaz4 as a platform technology with potential across a wide variety of human health applications, aiming to improve clinical outcomes, reduce costs, and address unmet needs in healthcare. As of the company's own disclosures, the Plaz4 product has not yet been approved by the U.S. Food and Drug Administration and is not currently for sale. Plasmology4 is privately held, and its headquarters are in Scottsdale, Arizona. The company's public communications emphasize the scientific foundations of plasma medicine, which combines plasma science, physics, life science, and clinical medicine.

Plasmology4 is a privately held technology company headquartered in Scottsdale, Arizona, United States. It operates in the emerging field of plasma medicine, which combines plasma science, physics, life science, and clinical medicine to advance non-thermal plasma technology for healthcare applications. The company's core proprietary platform is branded Plaz4, described as a novel non-thermal plasma with advanced characteristics compared to ordinary cold plasmas. Non-thermal plasma is ionized gas consisting of positive ions and free electrons, generated under earth atmospheric conditions at temperatures below 100°C (212°F). Plasmology4 positions Plaz4 as a platform technology with potential across a wide variety of human health applications. Its first product, the Plaz4 1000 system, is intended to address antibiotic-resistant bacteria and non-healing chronic wounds. The company reports that results from its in vitro studies and in vivo animal studies demonstrate that Plaz4 simultaneously kills pathogens, including antibiotic-resistant strains, and heals wounds in a way that is drug-free, painless, fast, and cost-effective. As of the company's public disclosures, the Plaz4 product has not yet been approved by the U.S. FDA and is not currently for sale. The company remains privately held.

Pioneering plasma medicine with proprietary Plaz4 non-thermal plasma platform technology for healthcare.

• Plaz4 1000 system

  First product from Plasmology4, a system based on Plaz4 non-thermal plasma technology intended to address antibiotic-resistant bacteria and non-healing chronic wounds. Not yet FDA-approved and not currently for sale.

1. 1Home - Plasmology4plasmology4.com
2. 2Plasmology4 (United States) - Wikidatawikidata.org